apremilast,deucravacitinib
bms,amgen
['deucra']
wcd 2023 day 3 afternoon - long term efficacy of deucravacitinib dr. ronald b. vender discusses the tyk2 inhibitor deucravacitinib at the #wcd2023 in #singapore 
Up-to-date clinical news for dermatology. Publishers of The Chronicle of Skin & Allergy, The Chronicle of Cosmetic Medicine & Surgery, & Skin Spectrum Summit